OrthoXel is an orthopaedic trauma device company focused on evolving fracture fixation through evidence-based biomechanical implant design. The Company thoughtfully designed its flagship Apex Tibial and Femoral Nails with a focus on fundamental principles of bone healing, all while keeping the surgeon’s needs in mind. Every OrthoXel product features innovative locking modes not found in any other implant system on the market and all are meticulously designed and engineered to produce the best possible clinical results for every patient.  

Will you be attending AAOS this year? SmartTRAK will be exhibiting (booth #6847) and we’re hoping to schedule a quick meeting to check-in with you and learn how we can better meet your needs. 

We’ll also have several SmartTRAK analysts on-site consulting with customers. Have questions about market numbers or want to know more about the latest technologies on the market? Maybe you have some questions about our latest market recap or where the market is going?

Stem cell “secretome” is the latest advancement in regenerative medicine. Will it become the heart of tissue regeneration? SmartTRAK interviewed Dr. Robert Keller, Ph.D, Chief Science Officer of Axolotl Biologix to learn more about the Company’s platform and future plans.

The core of regenerative medicine and leveraging the abilities of stem cells and their products to repair diseased or damaged tissues has focused in two main areas, harvesting progenitor cells and the “paracrine effect” of the stem cell secretome.

Recent studies suggest that the benefits of stem cell therapy and the underlying mechanism of repair might relate more to a paracrine modulatory effect rather than the replacement of damaged cells at the site. The secreted factors from the transplanted stems cells have been shown to trigger the patient's own cells to repair the tissue themselves.

One company that is harnessing the power of the stem cell secretome is Axolotl Biologics. Started in 2016, Axolotl Biologics offers human amnion-derived mesenchymal stromal cell (hAMSCs) conditioned medium that contains hAMSCs paracrine factors which can be used in various applications in orthopedics, wound care, pain management, ophthalmology, cardiovascular and cosmetics.

At the 6th ICRS Summit, Bio-Orthopaedics in Sports Medicine, held in San Diego, January 17 and 18, 2019, SmartTRAK caught up with Axolotl Biologix’ Chief Science Officer, Robert Keller, Ph.D. to discuss regenerative medicine and the Company’s progress.

Click on the video below to view the fascinating interview,  scroll down to read a transcript of the interview or download a PDF of the interview by clicking the link below.

Frederique Buntoum (aka Freddy) has joined BioMedGPS as Senior Analyst, Regenerative Medicine, overseeing the Cell Processing, Amniotic Tissue and Joint Fluid modules. Formerly Senior Manager of Market Insights at Bioventus, Freddy has broad experience in sales, marketing and competitive intelligence. Her passion for market research and uncovering the “why” behind industry developments complements SmartTRAK’s team of domain experts and her thoughtful and keen insights and out-of-the-box perspective on market happenings make her a great addition to the SmartTRAK analyst team.

In addition to her role as an analyst, Freddy will also be assisting with consulting projects and product development initiatives – two key areas that will contribute to BioMedGPS growth in 2019.

Freddy will be representing SmartTRAK at the upcoming AAOS meeting. Please Contact us if you would like to set up a time to meet.

Anne Staylor, Managing Editor, Business Intelligence and Senior Director, Advanced Technologies will be representing BioMedGPS SmartTRAK at both conferences. Please Contact Usif you would like a meeting!

New Products, Continued Demand Provide SCS Market Tailwinds

SmartTRAK reports that with new products providing a strong tailwind in Q318, the SCS market saw another quarter of strong double-digit growth in both the US and WW, positioning the market for another record year. 

Among the many topics covered in the Q318 SCS Market Recap are:

Well-rounded portfolios leading to strong Q318 for Soft Tissue Fixation

SmartTRAK reports that the continued rounding out of portfolios is leading to some commoditization in the market, but also allowing companies to capitalize on the strength of their sales forces in new portions of the Sports Medicine Market. High single and double-digit growth reported...

Among the many topics covered in the Q318 Soft Tissue Fixation Market Recap are:

SUTUREGARD is on a mission to close more wounds simply and safely

Company Overview

Founded in 2015 and based in Portland, Oregon, SUTUREGARD™ Medical, Inc. is a privately held medical device firm with patented technology that allows surgeons to perform simple closures of high-tension wounds through rapid intraoperative tissue expansion. For skin cancer surgeons (Mohs Surgeons), SUTUREGARD’s initial target market, the SUTUREGARD™ device allows closure of wounds using tissue expansion instead of relying on flaps, grafts, or second intent healing. This is particularly useful for scalp and lower leg closures. For some skin cancer surgeons, this will add greater efficiency to their day. For other skin cancer surgeons, this will retain closures in their practice that they would have otherwise sent to other specialists.

The Company founders — a Corvallis, Oregon-based skin cancer (Moh’s) surgeon and his Ph.D. nurse business partner — designed the SUTUREGARD device. The Company invested three years conducting bench research, pre-clinical studies, and customer discovery prior to completion of a successful human use study in 2018.

“SUTUREGARD Medical launched the SUTUREGARD device in November, 2018 at the Fundamentals of Mohs Surgery Conference and the product was enthusiastically received by surgeons.”   Dan Ladizinsky, MD, CEO of SUTUREGARD Medical.

SmartTRAK identifies trends to watch in spinal cord stimulation 

With the start of a new year, it's time to look back at 2018 and identify continuing and emerging trends in the market for Spinal Cord Stimulation (SCS) that are likely to shape the landscape in 2019 and beyond.

So what’s on the horizon? Anne Staylor, SmartTRAK Managing Editor, gives her predictions for the top technology and market trends to watch.

Among the many interesting and informative topics covered in the article are:

In an interview with SmartTRAK, B. Todd Sitzman, MD, MPH, President of the North American Neuromodulation Society (NANS), provides a preview of the educational opportunities, key research and emerging technologies that will be at the NANS 22^nd Annual meeting to be held January 17-20, 2019 in Las Vegas, NV. Dr. Sitzman expects NANS 2019 to be the biggest meeting yet for the premier neuromodulation society, with up to 3000 attendees and 300+ abstracts presented, organized around the theme of “The Science Behind Successful Outcomes.”

To find out more about the meeting, click on the video below to listen to SmartTRAK’s interview with Dr. Sitzman, recorded via Skype from his office in Hattiesburg, Mississippi (11:53 minutes).